Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A supratentorial ependymoma that has material basis in YAP1-MAMLD1 fusion.
No clinical trials have been registered for YAP1-MAMLD1 fusion-positive supratentorial ependymoma.
3 publications have been identified in PubMed for YAP1-MAMLD1 fusion-positive supratentorial ependymoma. Research spans Other (33%), Review / Meta-Analysis (33%), and Basic Science / Preclinical (33%).
Tauziède-Espariat A (2025). [PMID: 39928140](https://pubmed.ncbi.nlm.nih.gov/39928140/). *Acta neuropathologica*. [Other]
Driskill JH (2024). [PMID: 40491864](https://pubmed.ncbi.nlm.nih.gov/40491864/). *Annual review of cancer biology*. [Basic Science / Preclinical]
Soni N (2024). [PMID: 38844368](https://pubmed.ncbi.nlm.nih.gov/38844368/). *AJNR. American journal of neuroradiology*. [Review / Meta-Analysis]
Data assembled from 2 of 12 sources · Last updated Sep 20, 2026, 5:41 PM UTC
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
Common questions about YAP1-MAMLD1 fusion-positive supratentorial ependymoma